Meeting
2016 Genitourinary Cancers Symposium
Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.
Authors
A. Oliver Sartor
Tulane University School of Medicine, New Orleans, LA
A. Oliver Sartor , Matthew R. Cooperberg , Andrew J. Armstrong , Nicholas J. Vogelzang , Jeffrey L. Vacirca , Mark C. Scholz , Shaker R. Dakhil , Luke T. Nordquist , Elisabeth I. Heath , Nancy N. Chang , Jennifer Susan LIll , Celestia S. Higano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01306890
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 194)
DOI
10.1200/jco.2016.34.2_suppl.194
Abstract #
194
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.
First Author: Celestia S. Higano
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2022 ASCO Annual Meeting
Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
First Author: Nicholas D. James
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco